scholarly journals Chromatin profiling across the human tumour necrosis factor gene locus reveals a complex, cell type-specific landscape with novel regulatory elements

2008 ◽  
Vol 36 (15) ◽  
pp. 4845-4862 ◽  
Author(s):  
Jennifer M. Taylor ◽  
Kate Wicks ◽  
Claire Vandiedonck ◽  
Julian C. Knight
Keyword(s):  
Tumour Necrosis ◽  
Gene Locus ◽  
Regulatory Elements ◽  
Complex Cell ◽  
Cell Type ◽  
Human Tumour ◽  
Human Tumour Necrosis Factor ◽  
Cell Type Specific ◽  
Chromatin Profiling ◽  
Necrosis Factor

Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin

Nature ◽  
1984 ◽  
Vol 312 (5996) ◽  
pp. 724-729 ◽  
Author(s):  
Diane Pennica ◽  
Glenn E. Nedwin ◽  
Joel S. Hayflick ◽  
Peter H. Seeburg ◽  
Rik Derynck ◽  
...  
Keyword(s):  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Human Tumour ◽  
Precursor Structure ◽  
Human Tumour Necrosis Factor ◽  
Necrosis Factor

Expression and rescuing of a cloned human tumour necrosis factor gene using an EBV-based shuttle cosmid vector.

1987 ◽  
Vol 6 (2) ◽  
pp. 355-361 ◽  
Author(s):  
D. Kioussis ◽  
F. Wilson ◽  
C. Daniels ◽  
C. Leveton ◽  
J. Taverne ◽  
...  
Keyword(s):  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Human Tumour ◽  
Factor Gene ◽  
Human Tumour Necrosis Factor ◽  
Cosmid Vector ◽  
Necrosis Factor

Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor

Nature ◽  
1985 ◽  
Vol 313 (6005) ◽  
pp. 803-806 ◽  
Author(s):  
Takashi Shirai ◽  
Hiroshi Yamaguchi ◽  
Hirataka Ito ◽  
Chas. W. Todd ◽  
R. Bruce Wallace
Keyword(s):  
Escherichia Coli ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Cloning And Expression ◽  
Human Tumour ◽  
Expression In Escherichia Coli ◽  
Human Tumour Necrosis Factor ◽  
Necrosis Factor

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

1991 ◽  
Vol 10 (13) ◽  
pp. 4025-4031 ◽  
Author(s):  
J. Keffer ◽  
L. Probert ◽  
H. Cazlaris ◽  
S. Georgopoulos ◽  
E. Kaslaris ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Genetic Model ◽  
Human Tumour ◽  
Human Tumour Necrosis Factor ◽  
Necrosis Factor

Model for Whole Body Production of Tumour Necrosis Factor-α in Experimental Endotoxaemia in Healthy Subjects

1994 ◽  
Vol 87 (4) ◽  
pp. 459-465 ◽  
Author(s):  
R. Koopmans ◽  
F. J. Hoek ◽  
S. J. H. van Deventer ◽  
T. van der Poll
Keyword(s):  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Whole Body ◽  
Serum Concentrations ◽  
Tumour Necrosis Factor Α ◽  
Human Tumour ◽  
Human Tumour Necrosis Factor ◽  
Body Production ◽  
Factor Α ◽  
Necrosis Factor

1. Tumour necrosis factor-α is considered an important mediator in the pathophysiology of several diseases. Although much information is available about the serum concentrations of this cytokine in these illnesses, little is known about the production of tumour necrosis factor-α in disease in vivo. 2. In the present study we aimed to estimate the extent and the kinetics of whole body tumour necrosis factor-α synthesis in experimental endotoxaemia in six healthy humans. For this purpose we first examined the pharmacokinetic behaviour of an intravenously injected bolus of recombinant human tumour necrosis factor-α (50 μg/m2) in another group of six normal subjects. We then calculated the total amount of tumour necrosis factor-α produced after intravenous injection of endotoxin (2 ng/kg) as the product of the systemic clearance of recombinant human tumour necrosis factor-α (9.5 ± 5.0 ml min−1 kg−1) and the area under the tumour necrosis factor-α concentration-time curves in the endotoxaemic subjects. 3. Recombinant human tumour necrosis factor-α showed evident two-compartment kinetics with an initial rapid disappearance (t1/2 5.1 ± 2.2 min) and a terminal slower elimination (t1/2 49 ± 5 min). Tumour necrosis factor-α synthesis after endotoxin varied markedly between individuals, ranging from 11.8 to 114.1 μg (52.7 ± 34.7 μg). The changes in time of the serum concentrations of tumour necrosis factor-α after administration of endotoxin could be accurately described with an adapted two-compartment open model that incorporated both rapid tumour necrosis factor-α production (74% of the total amount) and slow tumour necrosis factor-α production (26%). 4. Our results suggest that, in endotoxaemia, circulating tumour necrosis factor-α originates from two different sources, one in rapid and one in slow equilibrium with the circulation. We propose that the pharmacokinetic characteristics of intravenous recombinant human tumour necrosis factor-α may be used to estimate the production of rumour necrosis factor-α in clinical disease.

Sign in / Sign up

Export Citation Format

Share Document